Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice…
Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa (andexanet alfa) in patients on oral FXa-inhibitor treatment including apixaban and rivaroxaban…
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023 Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated cancers, at the American Society of…
Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa Novartis announced today that the European Commission (EC) has approved Cosentyx® (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an…
Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib; CDK4/6 inhibitor) and Jaypirca™ (pirtobrutinib; non-covalent (reversible) BTK inhibitor) data to be presented at the 2023 ASCO® Annual Meeting in Chicago, June…
WHO launches a single-source repository on drug dependence information The repository, from WHO’s Expert Committee on Drug Dependence (ECDD), is an important resource for health professionals, drug policy experts and policy-makers, as many of the substances reviewed by ECDD have otherwise…
Lynparza plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the US for the treatment of adult patients with…
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical…
Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy Development Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has…
Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) Ultomiris (ravulizumab) has been approved in Japan as the first and only long-acting C5 complement inhibitor for the prevention of relapses in patients with…
Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy Positive high-level results from the DUO-E Phase III trial showed Imfinzi (durvalumab) in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib)or Imfinzi alone as maintenance therapy…
EUROPEAN STUDY FINDS THE ABBOTT CARDIOMEMS SENSOR RESULTS IN IMPROVED QUALITY OF LIFE AND 44% REDUCTION IN HEART FAILURE HOSPITALIZATIONS New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott’s CardioMEMS™ HF System resulted in a significant1 improvement…